ArticleFoods (Basel, Switzerland)2026
Methylxanthine Content in Green Tea Supplements: UHPLC Quantification, Method Validation, and Implications for Ergogenic Dosing in Athletes.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Green tea supplements (GTSs) are a favorite among the general population and, due to their methylxanthine (caffeine, theobromine, theophylline) content, might represent a potential ergogenic source in athletes' performance. The aim of this study was to develop and validate a method that quantifies the methylxanthine content of commercially available GTSs and to evaluate their potential relevance for ergogenic use. An ultra-high-performance liquid chromatography coupled with photodiode array detection and a QDa mass detector (UHPLC-PDA-QDa) method was developed, validated and applied to determine the content of methylxanthines in seven commercially available GTSs. Method validation parameters demonstrated satisfactory performance, with rapid and efficient separation and quantification of the three methylxanthines. Considerable variability was observed among the analyzed products, with caffeine, theobromine, and theophylline contents ranging from 0.37 to 12.13, 0.07 to 3.59, and 0.05 to 0.83 mg/capsule, respectively. However, the methylxanthine amounts measured in the analyzed products were below the doses commonly associated with ergogenic effects. Overall, the developed UHPLC-PDA-QDa method provided a reliable approach for methylxanthine quantification, while the seven products analyzed did not represent meaningful ergogenic sources of these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.